Japan· JP-7229401A1035
エドロホニウム塩化物
A edrophonium product containing エドロホニウム塩化物, registered in Japan by 杏林製薬, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Edrophonium is registered in 2 of 19 countries.
Countries holding a registration under ATC V04CX07 (edrophonium), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
Edrophonium · ATC V04CX07
2 / 19 countries
- Japan
- United Kingdom
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- エドロホニウム塩化物
- Manufacturer
- 杏林製薬
- Country
- Japan (JP)
- ATC code
- V04CX07
- ATC class
- Edrophonium
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
71 interactions on record for edrophonium.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Edrophonium · interactions on record
71 records
- 2 severe
- 69 moderate
Most severe, free to view
- SiponimodL04AA42severe
- SiponimodL04AE03severe
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Edrophonium in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomEdrophonium chloride 10mg/1ml solution for injection ampoulesAlliance Healthcare (Distribution) Ltd
- SpainANTICUDE 12,5 mg/ml SOLUCION INYECTABLEMana Pharma S.L.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Spain · Anticude
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b5ddc823-e3a5-4551-9380-0894774ddf32 GET /v1/drugs/b5ddc823-e3a5-4551-9380-0894774ddf32?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１％１ｍＬ１管",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "7229401A1035",
"category": "注射薬",
"price_yen": 109,
"generic_name": "エドロホニウム塩化物",
"product_name_jp": null,
"therapeutic_class": "7229",
"transitional_expiry": null
}See everything about edrophonium.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.